Pegaptanib: Difference between revisions

Pegaptanib
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

Newer edit →

VisualWikitext

Revision as of 21:35, 13 February 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Pegaptanib is a Ophthalmologic Agent that is FDA approved for the treatment of neovascular (wet) age-related macular degeneration. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration.

Dosage

Single-use glass syringe pre-filled with 0.3 mg of Macugen® in a nominal 90 μL solution for intravitreal injection.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pegaptanib in adult patients.

Non–Guideline-Supported Use

Diabetic macular edema^[1]

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Pegaptanib in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pegaptanib in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pegaptanib in pediatric patients.

Contraindications

Condition1

Warnings

Description

Precautions

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Pegaptanib in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Pegaptanib in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pegaptanib in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pegaptanib during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Pegaptanib with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Pegaptanib with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Pegaptanib with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Pegaptanib with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pegaptanib with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pegaptanib in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pegaptanib in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pegaptanib in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pegaptanib in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Pegaptanib in the drug label.

Description

IV Compatibility

There is limited information regarding IV Compatibility of Pegaptanib in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Pegaptanib in the drug label.

Pharmacology

There is limited information regarding Pegaptanib Pharmacology in the drug label.

Mechanism of Action

Structure

File:Pegaptanib01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Pegaptanib in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Pegaptanib in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Pegaptanib in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Pegaptanib in the drug label.

How Supplied

Storage

There is limited information regarding Pegaptanib Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Pegaptanib |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Pegaptanib |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Pegaptanib in the drug label.

Precautions with Alcohol

Alcohol-Pegaptanib interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

®^[2]

Look-Alike Drug Names

A® — B®^[3]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ; et al. (2005). "A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema". Ophthalmology. 112 (10): 1747–57. doi:10.1016/j.ophtha.2005.06.007. PMID 16154196.
↑ Empty citation (help)
↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Pegaptanib
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Pegaptanib
 |Label Name=Pegaptanib11.png

}}

{{#subobject:

 |Label Page=Pegaptanib
 |Label Name=Pegaptanib11.png

}}

[pmid16154196-1] Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ; et al. (2005). "A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema". Ophthalmology. 112 (10): 1747–57. doi:10.1016/j.ophtha.2005.06.007. PMID 16154196.

[2] Empty citation (help)

[www.ismp.org-3] "http://www.ismp.org". External link in |title= (help)

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
-|authorTag=<!--Overview-->
+|authorTag=<!--Overview-->{{RB}}
+|genericName=Pegaptanib sodium
 |aOrAn=a
-|hasBlackBoxWarning=Yes
+|drugClass= Ophthalmologic Agent
-|adverseReactions=<!--Black Box Warning-->
+|indicationType=treatment
+|indication=neovascular (wet) age-related macular degeneration
+|adverseReactions=
+<!--Black Box Warning-->
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
@@ Line 12: / Line 18: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult=====Indications====
+* Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-* Dosing Information
-:* Dosage
-=====Condition3=====
-* Dosing Information
-:* Dosage
-=====Condition4=====
-* Dosing Information
-:* Dosage
-<!--Off-Label Use and Dosage (Adult)-->
-<!--Guideline-Supported Use (Adult)-->
-|offLabelAdultGuideSupport======Condition1=====
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
+====Dosage====
+* Single-use glass syringe pre-filled with 0.3 mg of Macugen® in a nominal 90 μL solution for intravitreal injection.
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Non–Guideline-Supported Use (Adult)-->
-|offLabelAdultNoGuideSupport======Condition1=====
+|offLabelAdultNoGuideSupport=* Diabetic macular edema<ref name="pmid16154196">{{cite journal| author=Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ et al.| title=A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. | journal=Ophthalmology | year= 2005 | volume= 112 | issue= 10 | pages= 1747-57 | pmid=16154196 | doi=10.1016/j.ophtha.2005.06.007 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16154196  }} </ref>
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Pediatric Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Pediatric)-->
-|fdaLIADPed======Condition1=====
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
-|offLabelPedGuideSupport======Condition1=====
+|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Developed by:
-* Class of Recommendation:
-* Strength of Evidence:
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Non–Guideline-Supported Use (Pediatric)-->
-|offLabelPedNoGuideSupport======Condition1=====
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-* Dosing Information
-:* Dosage
-=====Condition2=====
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Contraindications-->